We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+6.87%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$9.54B
AUM Growth
+$55.8M
Cap. Flow
-$1.48B
Cap. Flow %
-15.48%
Top 10 Hldgs %
82.65%
Holding
142
New
10
Increased
13
Reduced
15
Closed
7

Top Buys

Rank Stock Value
1
NTLA icon
Intellia Therapeutics
NTLA
+$28.3M
2
ACAD icon
Acadia Pharmaceuticals
ACAD
+$10.1M
3
MRUS
Merus
MRUS
+$9.82M
4
AAAP
Advanced Accelerator Applications S.A.
AAAP
+$6.94M
5
ALDR
Alder Biopharmaceuticals
ALDR
+$5.88M

Top Sells

Rank Stock Value
1
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$274M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.9M
3
OMER icon
Omeros
OMER
+$11.5M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$9.52M
5
IMGN
Immunogen Inc
IMGN
+$9.01M

Sector Composition

Rank Sector Weight
1 Healthcare 80.73%
2 Technology 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DMTX
51
DELISTED
Dimension Therapeutics, Inc
DMTX
$7.51M 0.08%
1,251,881
– –
AIMT
52
DELISTED
Aimmune Therapeutics
AIMT
$7.29M 0.08%
673,908
+423,908
+170% +$5.76M
VTAE
53
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$6.88M 0.07%
637,597
– –
SAGE
54
DELISTED
Sage Therapeutics
SAGE
$6.75M 0.07%
224,048
– –
AKTX
55
Akari Therapeutics
AKTX
$14.8M
$6.7M 0.07%
621
+126
+25% +$1.62M
PRQR icon
56
ProQR Therapeutics
PRQR
$243M
$5.97M 0.06%
1,234,095
-115,624
-9% -$595K
NTRA icon
57
Natera
NTRA
$35.7B
$5.43M 0.06%
450,000
– –
ALDR
58
DELISTED
Alder Biopharmaceuticals
ALDR
$5.43M 0.06%
+217,328
New +$5.88M
RARE icon
59
Ultragenyx Pharmaceutical
RARE
$2.49B
$5.42M 0.06%
110,894
-13,000
-10% -$841K
ARWR icon
60
Arrowhead Research
ARWR
$11.9B
$5.37M 0.06%
1,009,509
– –
CNCE
61
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$5.28M 0.06%
470,058
-25,850
-5% -$329K
AERI
62
DELISTED
Aerie Pharmaceuticals
AERI
$5.27M 0.06%
299,356
– –
NERV icon
63
Minerva Neurosciences
NERV
$192M
$5.19M 0.05%
+63,551
New +$4.04M
NDRM
64
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$4.96M 0.05%
305,000
– –
GNMX
65
DELISTED
Aevi Genomic Medicine Inc
GNMX
$4.89M 0.05%
880,539
+115,539
+15% +$607K
SYRS
66
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$3.71M 0.04%
+20,447
New +$3.71M
CPRX
67
DELISTED
Catalyst Pharmaceutical
CPRX
$3.64M 0.04%
5,122,153
-376,306
-7% -$303K
MCRB icon
68
Seres Therapeutics
MCRB
$46.1M
$3.63M 0.04%
6,250
– –
ECYT
69
DELISTED
Endocyte, Inc. Common Stock
ECYT
$3.63M 0.04%
1,130,577
-565,288
-33% -$2.07M
LOXO
70
DELISTED
Loxo Oncology, Inc
LOXO
$3.19M 0.03%
137,735
– –
CRIS icon
71
Curis
CRIS
$9.67M
$3.12M 0.03%
1,000
– –
RXDX
72
DELISTED
Ignyta, Inc.
RXDX
$3.1M 0.03%
571,000
– –
JUNO
73
DELISTED
Juno Therapeutics, Inc.
JUNO
$3.08M 0.03%
80,000
– –
TRVN
74
DELISTED
Trevena, Inc.
TRVN
$2.83M 0.03%
720
– –
CBIO
75
Crescent Biopharma
CBIO
$566M
$2.77M 0.03%
+3,812
New +$2.63M
1 2
3
4 5

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q2 2016 Portfolio in Review

As of Q2 2016, Baker Bros. Advisors held 142 positions worth $9.54B, up 0.59% from $9.48B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Baker Bros. Advisors withdrew a net $1.48B in Q2 2016, closing 7 positions and reducing 15 holdings. Its most notable exit was ANACOR PHARMACEUTICALS INC COM, an estimated $274M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 77% a quarter earlier, followed by Technology.

Against the trend, Baker Bros. Advisors opened a new position in Intellia Therapeutics worth $22.7M.

  • Baker Bros. Advisors's largest Q2 2016 buy was Intellia Therapeutics: 1,062,120 shares worth $22.7M.
  • Baker Bros. Advisors added most to Acadia Pharmaceuticals in Q2 2016, an estimated $10.1M increase.
  • Baker Bros. Advisors's biggest Q2 2016 reduction was Mirati Therapeutics, Inc. Common Stock, cutting an estimated $15.9M.
  • Baker Bros. Advisors fully exited ANACOR PHARMACEUTICALS INC COM in Q2 2016, selling an estimated $274M.
  • Baker Bros. Advisors's ten largest holdings make up 83% of its $9.54B portfolio in Q2 2016.
  • Baker Bros. Advisors opened 10 new positions and closed 7 in Q2 2016.
  • Baker Bros. Advisors's portfolio value rose 0.59% quarter-over-quarter to $9.54B.

Based on Baker Bros. Advisors's 13F filing for Q2 2016, filed 15 Aug 2016.